Early detection and visualization of human adenovirus serotype 5-viral vectors carrying foot-and-mouth disease virus or luciferase transgenes in cell lines and bovine tissues

Vaccine

Volumn 30, Issue 9, 2012, Pages 1690-1701

  Montiel, Nestor ^a   Smoliga, George ^a   Arzt, Jonathan ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

Author keywords

Adenovirus; Cattle; FMDV; Hexon; Luciferase; Microscopy; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; FOOT AND MOUTH DISEASE VACCINE; LUCIFERASE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; COW; FOOT AND MOUTH DISEASE; GENETIC CODE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INOCULATION; INTERSTITIUM; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE; VIRUS DETECTION; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ANIMALS; CATTLE; CATTLE DISEASES; CELL LINE; DNA, VIRAL; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GENETIC VECTORS; HUMANS; LUCIFERASES; LYMPH NODES; MALE; RNA, VIRAL; TRANSGENES; VIRAL VACCINES;

EID: 84856803539     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.082     Document Type: Article

References (41)

1. Fauquet C., Mayo M., Maniloff J., Desselberger U., Ball L. Virus taxonomy: VIIIth report of the International Committee on Taxonomy of Viruses 2005, Elsevier Academic Press, San Diego, CA.
2. Arzt J., Juleff N., Zhang Z., Rodriguez L.L. The pathogenesis of foot-and-mouth disease I: viral pathways in cattle. Transboundary and Emerging Diseases 2011, 58(August (4)):291-304.
3. Brown F. The history of research in foot-and-mouth disease. Virus Research 2003, 91(January (1)):3-7.
4. Grubman M.J., Baxt B. Foot-and-mouth disease. Clinical Microbiology Reviews 2004, 17(April (2)):465-493.
5. Bahnemann H.G. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Archives of Virology 1975, 47(1):47-56.
6. Doel T.R. FMD vaccines. Virus Research 2003, 91(January (1)):81-99.
7. Mayr G.A., Chinsangaram J., Grubman M.J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 1999, 263(October (2)):496-506.
8. Grubman M., Moraes M., Schutta C., Barrera J., Neilan J., Ettyreddy D., et al. Adenovirus serotype 5-vectored foot-and-mouth disease subunit vaccines: the first decade. Future Virology 2010, 5(1):51-64.
9. Pacheco J.M., Brum M.C., Moraes M.P., Golde W.T., Grubman M.J. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 2005, 337(July (2)):205-209.
10. Moraes M.P., Mayr G.A., Mason P.W., Grubman M.J. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 2002, 20(February (11-12)):1631-1639.
11. Rodriguez L.L., Gay C.G. Development of vaccines toward the global control and eradication of foot-and-mouth disease. Expert Review of Vaccines 2011, 10(March (3)):377-387.
12. Paielli D.L., Wing M.S., Rogulski K.R., Gilbert J.D., Kolozsvary A., Kim J.H., et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Molecular Therapy 2000, 1(March (3)):263-274.
13. Bernt K.M., Ni S., Gaggar A., Li Z.Y., Shayakhmetov D.M., Lieber A. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Molecular Therapy 2003, 8(November (5)):746-755.
14. Huang X., Zhuang L., Cao Y., Gao Q., Han Z., Tang D., et al. Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration. Molecular Cancer Therapeutics 2008, 7(June (6)):1624-1632.
15. Ying B., Toth K., Spencer J.F., Meyer J., Tollefson A.E., Patra D., et al. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Therapy 2009, 16(August (8)):625-637.
16. Chen D., Murphy B., Sung R., Bromberg J.S. Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function. Gene Therapy 2003, 10(June (11)):991-998.
17. Sheets R.L., Stein J., Manetz T.S., Andrews C., Bailer R., Rathmann J., et al. Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Toxicological Sciences 2006, 91(June (2)):620-630.
18. Hiltunen M.O., Turunen M.P., Turunen A.M., Rissanen T.T., Laitinen M., Kosma V.M., et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB Journal 2000, 14(November (14)):2230-2236.
19. Plog M.S., Guyre C.A., Roberts B.L., Goldberg M., St George J.A., Perricone M.A. Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. Human Gene Therapy 2006, 17(July (7)):705-716.
20. Sharma A., Bangari D.S., Tandon M., Pandey A., HogenEsch H., Mittal S.K. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 2009, 386(March (1)):44-54.
21. Manthorpe M., Cornefert-Jensen F., Hartikka J., Felgner J., Rundell A., Margalith M., et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Human Gene Therapy 1993, 4(August (4)):419-431.
22. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(March (4949 Pt. 1)):1465-1468.
23. Everett R.S., Gerrard D.E., Grant A.L. Factors affecting production of luciferase and epitope-tagged IGF-I in porcine muscle after DNA injection. Journal of Endocrinology 2000, 166(August (2)):255-263.
24. Torres J.M., Alonso C., Ortega A., Mittal S., Graham F., Enjuanes L. Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. Journal of Virology 1996, 70(June (6)):3770-3780.
25. Swaney L.M. A continuous bovine kidney cell line for routine assays of foot-and-mouth disease virus. Veterinary Microbiology 1988, 18(September (1)):1-14.
26. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. The Journal of General Virology 1977, 36(July (1)):59-74.
27. Pacheco J.M., Piccone M.E., Rieder E., Pauszek S.J., Borca M.V., Rodriguez L.L. Domain disruptions of individual 3B proteins of foot-and-mouth disease virus do not alter growth in cell culture or virulence in cattle. Virology 2010, 405(September (1)):149-156.
28. Wilson W.C., Letchworth G.J., Jimenez C., Herrero M.V., Navarro R., Paz P., et al. Field evaluation of a multiplex real-time reverse transcription polymerase chain reaction assay for detection of vesicular stomatitis virus. Journal of Veterinary Diagnostic Investigation 2009, 21(March (2)):179-186.
29. Arzt J., Pacheco J.M., Rodriguez L.L. The early pathogenesis of foot-and-mouth disease in cattle after aerosol inoculation: identification of the nasopharynx as the primary site of infection. Veterinary Pathology 2010, (June).
30. Callahan J.D., Brown F., Osorio F.A., Sur J.H., Kramer E., Long G.W., et al. Use of a portable real-time reverse transcriptase-polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus. Journal of the American Veterinary Medical Association 2002, 220(June (11)):1636-1642.
31. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Analytical Biochemistry 1985, 150(October (1)):76-85.
32. Arzt J., Gregg D.A., Clavijo A., Rodriguez L.L. Optimization of immunohistochemical and fluorescent antibody techniques for localization of foot-and-mouth disease virus in animal tissues. Journal of Veterinary Diagnostic Investigation 2009, 21(November (6)):779-792.
33. Kalyuzhniy O., Di Paolo N.C., Silvestry M., Hofherr S.E., Barry M.A., Stewart P.L., et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(April (14)):5483-5488.
34. Muruve D.A., Cotter M.J., Zaiss A.K., White L.R., Liu Q., Chan T., et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. Journal of Virology 2004, 78(June (11)):5966-5972.
35. Muruve D.A. The innate immune response to adenovirus vectors. Human Gene Therapy 2004, 15(December (12)):1157-1166.
36. Schiaffino S., Partridge T. Skeletal muscle repair and regeneration. Advances in Muscle Research 2008, 3:380.
37. St Pierre B.A., Tidball J.G. Differential response of macrophage subpopulations to soleus muscle reloading after rat hindlimb suspension. Journal of Applied Physiology 1994, 77(July (1)):290-297.
38. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annual Review of Immunology 2001, 19:65-91.
39. Laskin D.L., Pendino K.J. Macrophages and inflammatory mediators in tissue injury. Annual Review of Pharmacology and Toxicology 1995, 35:655-677.
40. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(March (6673)):245-252.
41. Steinman R.M., Inaba K., Turley S., Pierre P., Mellman I. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Human Immunology 1999, 60(July (7)):562-567.